



[Billing Code: 4140-01-P]

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Drug Abuse Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

NIDA Research Education Program for Clinical Researchers and  
Clinicians (R25)

Date: November 27, 2018

Time: 10:00 AM to 12:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard

Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH, DHHS  
6001 Executive Boulevard, Room 4234, MSC 9550  
Bethesda, MD 20892  
301-827-5840  
julia.berzhanskaya@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel  
Multi-Site Studies for System-Level Implementation of Substance Use  
Prevention and Treatment Services (R01; R34)

Date: November 27, 2018

Time: 1:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health  
Neuroscience Center  
6001 Executive Boulevard  
Rockville, MD 20852  
(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH, DHHS  
6001 Executive Boulevard, Room 4234, MSC 9550  
Bethesda, MD 20892  
301-827-5840  
julia.berzhanskaya@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel  
Workshops on the Use of Adolescent Brain Cognitive Development  
(ABCD) Data (R25 Clinical Trial Not Allowed)

Date: November 29, 2018

Time: 10:00 AM to 11:30 AM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health  
Neuroscience Center  
6001 Executive Boulevard  
Rockville, MD 20852  
(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.

Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH, DHHS  
6001 Executive Boulevard, Room 4234, MSC 9550  
Bethesda, MD 20892  
301-827-5840  
julia.berzhanskaya@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel  
Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial  
Optional)

Date: December 5, 2018

Time: 12:00 PM to 2:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health  
Neuroscience Center  
6001 Executive Boulevard  
Rockville, MD 20852  
(Telephone Conference Call)

Contact Person: Hiromi Ono, Ph.D.  
Scientific Review Officer

Office of Extramural Policy and Review  
National Institute on Drug Abuse  
National Institutes of Health, DHHS  
6001 Executive Boulevard, Room 4238, MSC 9550  
Bethesda, MD 20892  
301-827-5820  
hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel  
Advancing Exceptional Research on HIV/AIDS and Substance Abuse  
(R01, Clinical Trial Optional)

Date: December 13, 2018

Time: 12:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health  
Neuroscience Center  
6001 Executive Boulevard  
Rockville, MD 20852  
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
National Institute on Drug Abuse, NIH, DHHS

6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-827-5819

gml45a@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction  
Research Programs, National Institutes of Health, HHS)

Dated: November 16, 2018.

**Natasha M. Copeland,**

*Program Analyst,*

*Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-25427 Filed: 11/21/2018 8:45 am; Publication Date: 11/23/2018]